Primecap Management Co. CA Sells 7,818 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Primecap Management Co. CA lessened its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 0.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,080,461 shares of the company’s stock after selling 7,818 shares during the period. BeOne Medicines accounts for 1.3% of Primecap Management Co. CA’s portfolio, making the stock its 21st largest holding. Primecap Management Co. CA’s holdings in BeOne Medicines were worth $1,730,913,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Sequoia Financial Advisors LLC boosted its holdings in shares of BeOne Medicines by 4.1% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock worth $436,000 after buying an additional 50 shares during the period. Penserra Capital Management LLC raised its holdings in BeOne Medicines by 2.7% in the 3rd quarter. Penserra Capital Management LLC now owns 2,981 shares of the company’s stock worth $1,015,000 after acquiring an additional 79 shares during the period. Allianz Asset Management GmbH lifted its position in BeOne Medicines by 3.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 3,400 shares of the company’s stock worth $1,158,000 after acquiring an additional 100 shares during the last quarter. Blue Trust Inc. boosted its holdings in BeOne Medicines by 11.7% during the third quarter. Blue Trust Inc. now owns 967 shares of the company’s stock valued at $329,000 after acquiring an additional 101 shares during the period. Finally, Anchor Investment Management LLC acquired a new stake in shares of BeOne Medicines in the second quarter valued at about $26,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Price Performance

Shares of ONC stock opened at $351.92 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $196.45 and a 12 month high of $385.22. The company has a market capitalization of $38.59 billion, a P/E ratio of 690.04 and a beta of 0.52. The stock has a 50 day moving average of $336.49 and a two-hundred day moving average of $330.27. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ONC. Citizens Jmp boosted their price objective on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Sanford C. Bernstein raised BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target on the stock in a research report on Monday, January 12th. Barclays increased their price objective on BeOne Medicines from $385.00 to $394.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Jefferies Financial Group restated a “buy” rating and issued a $420.00 price objective on shares of BeOne Medicines in a research note on Monday, November 17th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of BeOne Medicines in a research note on Wednesday, December 17th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $381.46.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 75,631 shares of BeOne Medicines stock in a transaction on Monday, December 15th. The shares were sold at an average price of $307.79, for a total transaction of $23,278,465.49. Following the sale, the chief executive officer owned 24,369 shares in the company, valued at $7,500,534.51. The trade was a 75.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total transaction of $580,203.20. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 102,656 shares of company stock valued at $31,567,496. 6.62% of the stock is owned by company insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.